Did savara inc. (svra) mislead investors? levi & korsinsky investigates

New york, ny / access newswire / may 30, 2025 / levi & korsinsky notifies investors that it has commenced an investigation of savara inc. ("savara inc.") (nasdaq:svra) concerning possible violations of federal securities laws. on may 27, 2025, the company announced that the fda issued a refusal to file letter for its biologics license application for molbreevi, its lead drug candidate for autoimmune pap.
SVRA Ratings Summary
SVRA Quant Ranking